Eli Lilly Shares Jump 54% on 56% Revenue Growth and $12.8B Incretin Sales
JNJ•Eli Lilly’s stock surged 54% over nine months as revenue jumped 56% year-over-year to support a 47.4% annual growth pace and an operating margin of 47.3%. Incretin franchise sales hit $12.8 billion in a quarter while FDA approval of oral obesity pill Foundayo and biotech acquisitions bolster the long-term pipeline.
1. Exceptional Stock Repricing
Over the past nine months, Eli Lilly’s share value climbed 54%, reflecting a fundamental revaluation of the company rather than a short-term bounce. This surge far outpaced the S&P 500’s 15% return and added hundreds of billions in market value.
2. Robust Revenue and Margin Expansion
In its latest quarter, Lilly reported a 56% year-over-year revenue increase and a 47.4% growth rate over the trailing twelve months, well above its three-year average of 37.9%. The company converted sales into profit at a 47.3% operating margin, compared with a 35.3% average over the prior three years.
3. New Obesity Treatment Launch
Lilly secured FDA approval for Foundayo, the first oral incretin therapy launched with obesity as its initial indication. This pill targets a massive weight-management market and follows the success of injectable incretins like Mounjaro and Zepbound.
4. Strategic Pipeline Acquisitions
To fuel long-term growth, Lilly agreed to acquire clinical-stage biotechs including Orna Therapeutics and Centessa Pharmaceuticals. These deals aim to leverage the company’s cash flow to expand its innovation pipeline beyond current incretin therapies.
